Insider Selling: Sight Sciences (NASDAQ:SGHT) Insider Sells $25,231.50 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy Hayden sold 3,150 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $8.01, for a total value of $25,231.50. Following the transaction, the insider directly owned 256,590 shares in the company, valued at $2,055,285.90. The trade was a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sight Sciences Trading Up 0.9%

Shares of Sight Sciences stock opened at $7.11 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93. The business has a fifty day simple moving average of $4.35 and a two-hundred day simple moving average of $3.97. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $8.06. The company has a market capitalization of $375.92 million, a price-to-earnings ratio of -7.90 and a beta of 2.47.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. The company had revenue of $12.54 million during the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. Research analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Institutional Investors Weigh In On Sight Sciences

Several institutional investors have recently made changes to their positions in SGHT. KCK LTD. bought a new position in Sight Sciences during the 2nd quarter worth $18,069,000. Long Focus Capital Management LLC grew its holdings in shares of Sight Sciences by 39.7% during the 1st quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company’s stock worth $7,504,000 after purchasing an additional 887,876 shares in the last quarter. Americana Partners LLC bought a new position in shares of Sight Sciences in the second quarter worth $3,568,000. Acadian Asset Management LLC raised its stake in Sight Sciences by 127.7% in the first quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock valued at $1,033,000 after purchasing an additional 242,559 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Sight Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after purchasing an additional 102,609 shares during the period. 55.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on SGHT shares. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Thursday, August 28th. Wall Street Zen raised Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Citigroup lowered their target price on Sight Sciences from $4.50 to $4.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 7th. Lake Street Capital boosted their price target on Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sight Sciences in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.17.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.